Research programme: second-generation anti-fungal therapeutics - General Biologicals CorporationAlternative Names: P-113Du; P-113Duplicate; P-113Tri; P-113Triplicate
Latest Information Update: 07 Oct 2016
At a glance
- Originator Pacgen Life Science Corporation
- Class Antifungals; Peptide antibiotics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Candidiasis